Back to Newsroom

Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients

Single Largest Prospective Pan-Omic Study to Identify Key Biomarkers and Central Therapeutic Targets for Cardiovascular Diseases Has Completed Enrollment

RICHMOND, Va., May 27, 2014 – Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease, today announced that it has completed the enrollment of patients in its international, prospective GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study, months ahead of schedule. GLOBAL is the first pan-omic study designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis.

Click here to read more